MENLO PARK, Calif. and TIANJIN, China, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II DNA Sequencing System, and Suqian Lakeside Pangu Gene Company (SLPC) announced that SLPC has established a new genomics facility with 1,500 square meters of laboratory space in the Tianjin Dong Li Lake Technology Park, dedicated to using PacBio Single Molecule, Real-Time (SMRT®) Sequencing as the major sequencing platform for its translational medicine research projects.
"Our goal is to become an innovative high-tech enterprise," stated founder and CEO of SLPC, Dr. Zhang Yaozhou. "I believe that PacBio's platform provides the most complete and accurate sequencing data, and we are committed to applying this technology toward the improvement of human health."
SLPC purchased four PacBio RS II Sequencing Systems earlier this year and recently installed them at their newly dedicated facility. The company ultimately intends to focus on applications such as molecular-based approaches for early diagnosis of cancers, disease recurrence control and drug efficacy evaluation.
Ram Laxman, Ph.D., President & General Manager, Asia Pacific for Pacific Biosciences commented: "SLPC's investment in the PacBio RS II systems for human and other large genome sequencing follows a growing trend of researchers adopting the SMRT Sequencing technology to generate highly accurate complete genomes."
About the PacBio RS II and SMRT Sequencing
Pacific Biosciences' SMRT Sequencing technology achieves the industry's longest read lengths, highest consensus accuracy, and the least degree of bias. These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural, and industrial problems.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio RS II DNA Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; de novo genome assembly to more fully identify, annotate, and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses of the Company's products and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and could materially affect actual results. Factors that could materially affect actual results can be found in our filings with the Securities and Exchange Commission, including our most recent reports on Forms 10-K and 10-Q, and include those listed under the caption "Risk Factors." The Company undertakes no obligation to update forward-looking statements.
CONTACT: For Pacific Biosciences: Media: Nicole Litchfield 415.793.6468 email@example.com Investors: Trevin Rard 650.521.8450 firstname.lastname@example.orgSource:Pacific Biosciences of California, Inc.